CDK
Os inibidores das quinases dependentes de ciclinas (CDK) são compostos que bloqueiam a atividade das CDKs, um grupo de quinases de proteínas que regulam o ciclo celular, a transcrição e outros processos celulares. As CDKs são ativadas pela ligação às ciclinas, e sua atividade é crucial para a progressão das células através das diferentes fases do ciclo celular. Inibir as CDKs pode interromper a divisão celular, levando à parada do ciclo celular e à apoptose, especialmente em células cancerígenas onde as CDKs frequentemente estão desreguladas. Os inibidores de CDK são amplamente utilizados na pesquisa do câncer e têm potencial terapêutico no tratamento de vários tipos de câncer. Na CymitQuimica, oferecemos uma seleção abrangente de inibidores de CDK de alta qualidade para apoiar sua pesquisa em controle do ciclo celular, câncer e desenvolvimento terapêutico.
Foram encontrados 547 produtos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Roccellic Acid
CAS:Roccellic acid from R. montagnei lichen has antibacterial, anticancer properties; MIC 46.9 μg/ml; inhibits cancer cells by up to 87.9%.Fórmula:C17H32O4Cor e Forma:SolidPeso molecular:300.43CDK7-IN-21
CAS:CDK7-IN-21 (compound A22) is a potent CDK7 inhibitor [1] .Fórmula:C33H36FN9O2Cor e Forma:SolidPeso molecular:609.7Eciruciclib
CAS:Eciruciclib is an inhibitor of CDK with antitumor properties.Fórmula:C27H33FN8Pureza:99.73%Cor e Forma:SolidPeso molecular:488.6WAY-322243
CAS:WAY-322243 has antibacterial and anti-inflammatory activity and has an inhibitory effect on CLK-1, which can be used to study Alzheimer's disease.Fórmula:C18H18N2O2SPureza:99.88%Cor e Forma:SoildPeso molecular:326.41YJ9069
YJ9069 is a selective CDK12/CDK13P ROTAC degrader with an IC50 of 22.22 nM in VCaP cells. Rapid degradation of CDK12/13 by this compound triggers transcription elongation defects dependent on gene length, leading to DNA damage and cell cycle arrest. YJ9069 effectively inhibits the proliferation of prostate cancer cell subpopulations and significantly suppresses prostate tumor growth in vivo.Fórmula:C46H46N10O7Cor e Forma:SolidPeso molecular:850.92CPD-39
CAS:CPD-39 is an efficacious and orally active bifunctional PROTAC degrader targeting both CCND1 and CDK4. It exhibits antiproliferative effects.Fórmula:C46H57N15O4Cor e Forma:SolidPeso molecular:884.04CDK9-IN-27
CDK9-IN-27 (Compound 6a), a CDK9 inhibitor with an IC50 of 0.424 μM, induces apoptosis and S-phase cell cycle arrest.Fórmula:C23H18ClN5O3Pureza:98%Cor e Forma:SolidPeso molecular:447.87CDK7-IN-7
CAS:CDK7-IN-7: Selective CDK7 inhibitor, IC50 < 50 nM (Patent CN112661745A).Fórmula:C20H20BrF3N6O2Cor e Forma:SolidPeso molecular:513.319CDK5-IN-1
CAS:CDK5-IN-1: Potent CDK5 inhibitor (<10 nM) used in kidney disease research.Fórmula:C24H25FN6O3SCor e Forma:SolidPeso molecular:496.56IV-361
CAS:IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1Fórmula:C23H32FN5O2SiCor e Forma:SolidPeso molecular:457.625EGFR/CDK2-IN-2
EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.Fórmula:C49H32N12O2S2Pureza:98%Cor e Forma:SolidPeso molecular:884.99Multi-target kinase inhibitor 2
Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 valuesPureza:98%Cor e Forma:Odour SolidTMX-2039
CAS:TMX-2039 is a pan-CDK inhibitor that targets cell cycle CDKs (CDK1, CDK2, CDK4, CDK5, and CDK6) and transcription CDKs (CDK7 and CDK9), with IC50 values of 2.6, 1.0, 52.1, 0.5, 35.0, 32.5, and 25 nM, respectively. It serves as a ligand for the target protein in PROTAC applications.Fórmula:C17H20BrFN6O3SCor e Forma:SolidPeso molecular:487.347CDK2/PIM1-IN-1
CDK2/PIM1-IN-1 is an inhibitor of the kinases CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM). It can induce apoptosis (cell death) and reduce the expression of TNF-α, which promotes tumors. CDK2/PIM1-IN-1 exhibits antitumor activity.Cor e Forma:Odour SolidCDK8/19-IN-3
CDK8/19-IN-3 (compound 3-7) is a potent and selective inhibitor of CDK8 and CDK19. It can increase IL-10 levels and has potential for research in inflammatory bowel disease (IBD).Fórmula:C20H23FN6O2Cor e Forma:SolidPeso molecular:398.434CDK12-Cyclin K Ligand-Linker Conjugates 1
CDK12-Cyclin K Ligand-Linker Conjugates 1 is a Target Protein Ligand-Linker Conjugate that includes a CDK12-Cyclin K ligand and a PROTAC linker, which can recruit E3 ligase. CDK12-Cyclin K Ligand-Linker Conjugates 1 is applicable for the synthesis of PROTACPP-C8.Cor e Forma:Odour SolidWAY-647802
CAS:WAY-647802 is a CDK inhibitor.Fórmula:C11H14N4O3Pureza:99.53%Cor e Forma:SolidPeso molecular:250.25BSJ-04-132
Selective Cdk4 degrader. Degrades Cdk4 in Molt-4 cells, with no effect on Cdk6 levels. Displays cereblon-dependent degradation.Cor e Forma:Liquid(1S,3R,5R)-PIM447 dihydrochloride
(1S,3R,5R)-PIM447 (dihydrochloride) an inhibitor of PIM(IC50 of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3).Fórmula:C24H25Cl2F3N4OPureza:98%Cor e Forma:SolidPeso molecular:513.38CDK7-IN-6
CAS:CDK7-IN-6, a potent CDK7 inhibitor (IC50 ≤100 nM), from WO2019197549 A1, is >200x selective over CDK1/2/5, promising for cancer research.Fórmula:C26H34ClN9OCor e Forma:SolidPeso molecular:524.07TMX-2138
CAS:TMX-2138 is a CDKs PROTAC degrader, with IC50 values of 8.7 nM for CDK1/cyclinB, 10.9 nM for CDK2/cyclinA, 7.0 nM for CDK5/p25, and 25.7 nM for CDK9/cyclinT1. It enhances the ubiquitination and degradation of CDKs and is utilized for ovarian cancer research.Fórmula:C40H43BrFN9O11SCor e Forma:SolidPeso molecular:956.791CDK7-IN-2 hydrochloride hydrate
CAS:CDK7-IN-2 HCl hydrate is a potent, specific CDK7 enzyme inhibitor with significant anti-cancer effects.Fórmula:C26H42ClN7O4Cor e Forma:SolidPeso molecular:552.12LL-K8-22
LL-K8-22: potent CDK8/cyclin C degrader; DC50 ~2.5μM; hinders STAT1 phosphorylation; curbs E2F/MYC cancer pathways; for TNBC study.Fórmula:C37H43N5OCor e Forma:SolidPeso molecular:573.77FDA-Approved Kinase Inhibitor Library
A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.
Cor e Forma:LiquidCDK2/4-IN-1
CDK2/4-IN-1 (compound B-4a) serves as both a CDK2/4 inhibitor and a microtubule polymerization inhibitor, making it useful in cancer research.Cor e Forma:Odour SolidCimpuciclib
CAS:Cimpuciclib is a cyclin-dependent kinase(CDK) inhibitor and antineoplastic.Fórmula:C30H35FN8OCor e Forma:SolidPeso molecular:542.663CDK1-IN-2
CAS:CDK1-IN-2 (cdk1 inhibitor 2) is a CDK1 inhibitor with IC50 of 5.8 μM.Fórmula:C17H11ClN2OPureza:98.53%Cor e Forma:SoildPeso molecular:294.73Ref: TM-T64373
1mg50,00€1mL*10mM (DMSO)103,00€5mg107,00€10mg170,00€25mg354,00€50mg567,00€100mg810,00€500mg1.644,00€Olomoucine
CAS:Olomoucine hinders Cdk2, Cdc2, CDK5, ERK1, regulates the cell cycle, and fights melanoma; IC50s: 3-25 µM.
Fórmula:C15H18N6OPureza:99.77%Cor e Forma:White Crystalline PowderPeso molecular:298.34TL12-186
CAS:TL12-186 is a Cereblon-dependent kinase degrader that degrades CDK, BTK, FLT3, Aurora and other kinases.TL12-186 inhibits CDK2/cyclin A and CDK9/cyclin T1 withFórmula:C44H51ClN10O9SPureza:98.2%Cor e Forma:SolidPeso molecular:931.46Ref: TM-T34888
1mg69,00€2mg89,00€5mg147,00€10mg224,00€1mL*10mM (DMSO)245,00€25mg358,00€50mg512,00€100mg707,00€200mg973,00€YX-2-107
CAS:YX-2-107: CDK6-degrading PROTAC, IC50 of 4.4 nM, hinders RB phosphorylation/FOXM1, counters Ph+ ALL growth in rats, targets Ph+ ALL prophylaxis/treatment.Fórmula:C45H51N11O9Pureza:98.09% - 99.148%Cor e Forma:SolidPeso molecular:889.95CDK2-IN-7
CAS:CDK2-IN-7 is a CDK2 inhibitor for treating cancer ( IC 50 < 50 nM).Fórmula:C24H30N6O4SCor e Forma:SolidPeso molecular:498.6CDK9-IN-35
CDK9-IN-35 (compound 10j) acts as an inhibitor of CDK9/CyclinT1, exhibiting an IC50 of 10.2 nM. It also shows an IC50 of 20 nM against the HCT-116 cell line.Fórmula:C26H24ClFN4O4SCor e Forma:SolidPeso molecular:543.01Cell Cycle Compound Library
A unique collection of xnum cell cycle related compounds for high throughput screening (HTS) and high content screening (HCS);
Cor e Forma:Odour SolidCDK6/9-IN-1
CAS:CDK6/9-IN-1, an oral dual inhibitor of CDK6/9, has IC50s of 40.5nM (CDK6) and 39.5nM (CDK9).Fórmula:C22H25ClN8OCor e Forma:SolidPeso molecular:452.95CDK12/13-IN-2
CDK12/13-IN-2 (Compound 24) is a covalent inhibitor of CDK12 and CDK13, exhibiting IC50 values of 15.5 nM and 12.2 nM, respectively. It effectively inhibits the proliferation of breast cancer cells and can be utilized in the research of triple-negative breast cancer.Fórmula:C24H22FN7O2Cor e Forma:SolidPeso molecular:459.48CDK-IN-12
CAS:CDK-IN-12 (Example 20), a CDK inhibitor, effectively inhibits CDK4/6, demonstrating IC50 values below 20 nM [1].Fórmula:C26H29FN6OSCor e Forma:SolidPeso molecular:492.61JH-XVI-178
CAS:JH-XVI-178: potent CDK8/19 inhibitor with good pharmacokinetics, low clearance, moderate oral bioavailability.Fórmula:C22H22ClN7OCor e Forma:SolidPeso molecular:435.92Leucettine L41
CAS:Leucettine L41 (LeucettineL41) is an inhibitor of DYRKs/CLKs, preferentially targeting DYRK1A, and inhibits DYRK2.Fórmula:C17H13N3O3Pureza:99.08%Cor e Forma:SolidPeso molecular:307.3PROTAC CDK9 degrader 4
CAS:PROTAC CDK9 degrader 4 is a CDK9 degrader that targets transcriptional regulation and has potential anticancer activity.Fórmula:C43H56N10O5Cor e Forma:SolidPeso molecular:792.97CDK-IN-15
CAS:CDK-IN-15 (Compound 456) is an effective inhibitor of Cyclin A, exhibiting an IC50 value of 0.14 μM.Fórmula:C45H63Cl2F4N7O8Cor e Forma:SolidPeso molecular:976.92CP-10
CAS:CP-10, a selective PROTAC, degrades CDK6 (DC50: 2.1 nM) and inhibits hematopoietic cancers, including multiple myeloma.Fórmula:C44H49N13O7Pureza:98%Cor e Forma:SolidPeso molecular:871.94Ref: TM-T13627
100mgA consultar200mgA consultar5mg655,00€10mg897,00€1mL*10mM (DMSO)952,00€50mg1.972,00€Cdk2/Cyclin Inhibitory Peptide I
CDK2, a Ser/Thr kinase, is akin to yeast cdc28 and human Cdk1, crucial for cell division.Fórmula:C111H196N48O23Pureza:98%Cor e Forma:SolidPeso molecular:2571.05CDK4/6-IN-11
CAS:CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader.Fórmula:C43H49N11O7Cor e Forma:SolidPeso molecular:831.92CDK9 degrader-1
CDK9degrader-1 is a selective CDK9 degrader (DC50: 0.4073 µM). It recruits ATG101 to initiate the autophagy-lysosome pathway and forms autophagosomes by recruiting LC3, which then fuse with lysosomes to degrade CDK9 and its partner protein, Cyclin T1 (DC50: 1.215 µM). CDK9degrader-1 induces caspase 3-mediated apoptosis and exhibits antitumor activity in a mouse HCT116 xenograft model.Fórmula:C32H34Cl2N6O4Cor e Forma:SolidPeso molecular:637.56CDK7/9-IN-1
CAS:CDK7/9-IN-1 inhibits CDK7/9 with IC50: 0.0656 μM (no pre-incubation), 0.00574 μM (3h pre-inc.), and CDK9: 2.14 μM (3h pre-inc.) for cancer research.Fórmula:C24H32F3N5O2Cor e Forma:SolidPeso molecular:479.548Cdk2/Cyclin Inhibitory Peptide II
CAS:Cdk2/Cyclin Inhibitory Peptide II (Tat-LDL), a CDK2 inhibitor, demonstrates dose-dependent cytotoxic effects on U2OS osteosarcoma cells [1].Fórmula:C110H200N48O25Cor e Forma:SolidPeso molecular:2595.07SNX7
CAS:SNX7 (WAY-323879) inhibits CDKI pathway; useful for studying aging and related diseases.Fórmula:C15H14N2OPureza:99.96%Cor e Forma:SolidPeso molecular:238.28PROTAC CDK9 degrader-9
PROTAC CDK9 degrader-9 (compound 29) is a highly efficient, selective degrader of CDK9 based on PROTAC technology. It is utilized in cancer research.Fórmula:C42H51FN12O6Cor e Forma:SolidPeso molecular:838.93BSJ-03-204
CAS:BSJ-03-204 is a selective Cdk4/6 degrader.Fórmula:C43H48N10O8Cor e Forma:SolidPeso molecular:832.9JH-XI-10-02
CAS:JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.Fórmula:C53H69N5O9Pureza:98%Cor e Forma:SolidPeso molecular:920.161MeBIO
CAS:MeBIO is an agonist of aryl hydrocarbon receptor, with IC50 of 44 and 55 μM for GSK-3 and CDK1/CyclinB, respectively. MeBIO does not affect GSK-3β.Fórmula:C17H12BrN3O2Pureza:99.64%Cor e Forma:SolidPeso molecular:370.2Ref: TM-T21966
1mg39,00€5mg74,00€1mL*10mM (DMSO)86,00€10mg117,00€25mg220,00€50mg354,00€100mg520,00€500mg1.130,00€[pSer2, pSer5, pSer7]-CTD TFA
Substrate '[pSer2, pSer5, pSer7]-CTD (TFA)' for CDK7 phosphorylates RNA Pol II CTD at ser2, 5, 7.Fórmula:C98H138F3N21O39Pureza:98%Cor e Forma:SolidPeso molecular:2291.25NCT02
CAS:NCT02 degrades cyclin K, leading to CCNK and CDK12 degradation, potentially aiding metastatic CRC research.Fórmula:C17H16N2O2SCor e Forma:SolidPeso molecular:312.39CDK5-IN-3
CAS:CDK5-IN-3 is a selective and potent CDK5 inhibitor that inhibits CDK5/p25 and CDK2/CycA, and can be used in the study of cancer.Fórmula:C22H26N4OPureza:98.21%Cor e Forma:SolidPeso molecular:362.47Palbociclib-d8
CAS:Palbociclib-d8 (PD 0332991 D8) is the deuterated form of Palbociclib. Palbociclib is a CDK inhibitor that inhibits CDK4 and CDK6.Fórmula:C24H21D8N7O2Pureza:98%Cor e Forma:SolidPeso molecular:455.58SB1317
CAS:SB1317 (TG02) is a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3).Fórmula:C23H24N4OPureza:99.86%Cor e Forma:SolidPeso molecular:372.46TG003
CAS:TG003 is a Clk1/Sty inhibitor that inhibits Clk1 and Clk4, suppresses cancer cell growth, and induces apoptosis.Fórmula:C13H15NO2SPureza:99.46%Cor e Forma:SolidPeso molecular:249.33Ref: TM-T60367
1mg48,00€5mg92,00€10mg150,00€1mL*10mM (DMSO)167,00€25mg266,00€50mg440,00€100mg530,00€200mg767,00€LDC4297
CAS:LDC4297 (LDC044297) is a potent and selective CDK7 inhibitor.Fórmula:C23H28N8OPureza:98.25%Cor e Forma:SolidPeso molecular:432.52NU6102
CAS:NU6102 is a CDK2 inhibitor with antitumor activity against CDK1/cyclinB, CDK1/CDK2, CDK4, DYRK1A , PDK1, and ROCKII, and it can be used to study rectal cancer.Fórmula:C18H22N6O3SPureza:99.76%Cor e Forma:SolidPeso molecular:402.47Ribociclib hydrochloride
CAS:Ribociclib hydrochloride (LEE011 HCl) is a selective, orally active cyclin-dependent kinase CDK4/6 inhibitor (IC50=10/39 nM) that inhibits proliferation.Fórmula:C23H31ClN8OPureza:99.87%Cor e Forma:SolidPeso molecular:471GP-82996
CAS:GP-82996 (CINK4) inhibits CDK4/6; IC50s: 1.5 μM (CDK4/D1), 5.6 μM (CDK6/D1), 25 μM (Cdk5/p35); triggers U2OS cancer cell apoptosis.Fórmula:C27H32N6OPureza:99.94%Cor e Forma:SolidPeso molecular:456.58(E/Z)-Zotiraciclib hydrochloride
CAS:(E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride is a potent inhibitor of CDK2, JAK2, and FLT3.Fórmula:C23H25ClN4OCor e Forma:SolidPeso molecular:408.93Palbociclib hydrochloride
CAS:Palbociclib hydrochloride is the salt form of Palbociclib, a selective and orally available CDK4 and CDK6 inhibitor for breast and hepatocellular carcinoma.Fórmula:C24H31Cl2N7O2Pureza:99.89%Cor e Forma:SolidPeso molecular:520.46FMF-04-159-2
CAS:FMF-04-159-2 is a potent covalent CDK14 & CDK2 inhibito and is able to reduce α-Syn aggregation in neurons, and inhibits TNBC cancer progression.Fórmula:C28H30Cl3N7O5SPureza:96.57%Cor e Forma:SolidPeso molecular:683.01PROTAC CDK9 Degrader-1
CAS:PROTAC CDK9 Degrader-1 is a selective PROTAC-based CDK9 degrader, composed of a Cereblon ligand and a CDK ligand.Fórmula:C33H35N5O7Pureza:95.1%Cor e Forma:SolidPeso molecular:613.66Ribociclib-d6
CAS:Ribociclib-d6 is a deuterated compound of Ribociclib (LEE011) for isotope tracing.Ribociclib is an orally available CDK4/6 inhibitor with antitumor activity.Fórmula:C23H30N8OCor e Forma:SolidPeso molecular:440.57CDK9-IN-1
CAS:CDK9-IN-1 is a selective and potent CDK9 inhibitor with antiviral activity used in the study of PRRSV infections.Fórmula:C26H21N5O4SPureza:98.52%Cor e Forma:SolidPeso molecular:499.54TG-693
CAS:TG-693, Oral CLK1 inhibitor, promotes exon 31 skipping of dystrophin gene, inhibits CLK1 substrate phosphorylation, for Duchenne muscular dystrophy.Fórmula:C12H9N3Pureza:99.81%Cor e Forma:SolidPeso molecular:195.23Dalpiciclib hydrochloride
Dalpiciclib (SHR-6390) HCl is an oral CDK4/6 inhibitor with IC50s of 12.4/9.9 nM, an antitumor for breast and esophageal cancers.Fórmula:C25H31ClN6O2Cor e Forma:SolidPeso molecular:483.011-NM-PP1
CAS:1-NM-PP1 (PP1 Analog II) is a cell-permeable PP1 analog that acts as a potent and selective inhibitor of mutant kinases over their wild-type progenitors.Fórmula:C20H21N5Pureza:98% - 98.93%Cor e Forma:White Cyrstalline SolidPeso molecular:331.41Ref: TM-T2153
1mg48,00€2mg63,00€5mg84,00€1mL*10mM (DMSO)90,00€10mg132,00€25mg271,00€50mg505,00€100mg668,00€Atuveciclib
CAS:Atuveciclib Racemate is an oral CDK9 inhibitor with a 13 nM IC50, targeting P-TEFb/CDK9 selectively.Fórmula:C18H18FN5O2SPureza:98.8%Cor e Forma:SolidPeso molecular:387.43Ref: TM-T10464L
1mg84,00€2mg114,00€5mg192,00€1mL*10mM (DMSO)212,00€10mg313,00€25mg580,00€50mg773,00€100mg1.063,00€DRB
CAS:DRB is a nucleoside analog that inhibits several carboxyl-terminal domain (CTD) kinases including casein kinase II (IC50 range of 4-10 μM)
Fórmula:C12H12Cl2N2O4Pureza:99.46% - 99.83%Cor e Forma:White To Off-White Crystalline SolidPeso molecular:319.14PHA-767491 hydrochloride
CAS:PHA-767491 (CAY-10572) is a potent Cdc7/CDK9 inhibitor (IC50: 10/34 nM), selective against GSK3-β, CDK1/2, CDK5, MK2, CHK2, PLK1.Fórmula:C12H12ClN3OPureza:99.56% - 99.92%Cor e Forma:SolidPeso molecular:249.69Cdk5 Substrate acetate
Cdk5, a serine/threonine kinase active in neurons, phosphorylates proteins like histone H1; its synthetic substrate has a Km of 5 µM.Fórmula:C55H103N15O14Pureza:96.21%Cor e Forma:SolidPeso molecular:1198.5PF-06873600
CAS:PF-06873600: oral CDK inhibitor (CDK2/4/6), Ki 0.09-0.16 nM, potential anticancer drug.Fórmula:C20H27F2N5O4SPureza:98.77% - 99.55%Cor e Forma:SolidPeso molecular:471.52Ref: TM-T8463
1mg54,00€5mg114,00€1mL*10mM (DMSO)118,00€10mg178,00€25mg334,00€50mg557,00€100mg888,00€200mg1.198,00€AMG 925 HCl
CAS:AMG 925 HCl is a selective and potent dual inhibitor of FLT3 (IC50: 2±1 nM) and CDK4 (IC50: 3±1 nM).Fórmula:C26H30ClN7O2Cor e Forma:SolidPeso molecular:508.02CDK9-IN-30
CAS:CDK9-IN-30 is one of the Tat peptide derivatives and inhibits HIV-1 long terminal repeat-activated transcription.Fórmula:C16H20FNO3Pureza:99.75%Cor e Forma:SolidPeso molecular:293.33AZD-5438
CAS:AZD-5438 is an effective inhibitor of CDK, for CDK1(IC50=16 nM), CDK2(IC50=6 nM), CDK9(IC50=20 nM).Fórmula:C18H21N5O2SPureza:99.73% - 99.87%Cor e Forma:SolidPeso molecular:371.46Flavopiridol hydrochloride
CAS:Flavopiridol hydrochloride (MDL 107826A), an inhibitor of cyclin-dependent kinase, is a synthetic N-methylpiperidinyl chlorophenyl flavone compound.Fórmula:C21H21Cl2NO5Pureza:98.87% - 99.88%Cor e Forma:SolidPeso molecular:438.3AG-494
CAS:AG-494 (Tyrphostin B48) is an inhibitor of epidermal growth factor receptor kinase.Fórmula:C16H12N2O3Pureza:98.69%Cor e Forma:SolidPeso molecular:280.28Seliciclib
CAS:Seliciclib (Roscovitine) is a potent inhibitor of Cdk2/cyclin E, also inhibits Cdk7, Cdk5 and Cdc2. Seliciclib has antitumor effect. Cost-effective, quality assurance.Fórmula:C19H26N6OPureza:97.15% - 99.89%Cor e Forma:White To Off-White SolidPeso molecular:354.45Bromosporine
CAS:Bromosporine is a broad spectrum inhibitor for bromodomains for BRD2/4/9 and CECR2 (IC50: 0.41/0.29/0.122/0.017 μM), respectively.Fórmula:C17H20N6O4SPureza:99.65% - 99.79%Cor e Forma:SolidPeso molecular:404.44Ref: TM-T6255
1mg44,00€2mg57,00€1mL*10mM (DMSO)92,00€5mg93,00€10mg133,00€25mg260,00€50mg416,00€100mg665,00€200mg888,00€BSJ-03-123
CAS:BSJ-03-123 is a potent, CDK6-selective small-molecule degrader.Fórmula:C47H56N10O11Pureza:97.78% - 99.38%Cor e Forma:SolidPeso molecular:937.01Ref: TM-T5395
1mg87,00€2mg113,00€5mg177,00€10mg259,00€25mg409,00€50mg560,00€100mg800,00€500mg1.611,00€(E/Z)-Zotiraciclib
CAS:(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.Fórmula:C23H24N4OPureza:97.75% - 99.92%Cor e Forma:SolidPeso molecular:372.46Ref: TM-T21503
1mg43,00€2mg56,00€1mL*10mM (DMSO)90,00€5mg93,00€10mg113,00€25mg200,00€50mg330,00€100mg480,00€PF-562271 besylate
CAS:PF-562271 besylate: potent, ATP-competitive FAK inhibitor, IC50 1.5 nM, 10x less effective on Pyk2, highly selective vs other kinases.Fórmula:C21H20F3N7O3S·C6H6O3SPureza:97.65% - 99.01%Cor e Forma:SolidPeso molecular:665.66Ref: TM-T6177
1mg35,00€5mg74,00€1mL*10mM (DMSO)89,00€10mg94,00€25mg138,00€50mg198,00€100mg296,00€200mg427,00€Indirubin-3'-monoxime
CAS:Indirubin-3'-monoxime (Indirubin-3'-oxime) is a potent inhibitor of GSK3β (IC50: 22 nM) and also inhibits CDKs ( (IC50s: 100/180/250 nM for Cdk5/p35, Cdk1/Fórmula:C16H11N3O2Pureza:99.55%Cor e Forma:Dark Red SolidPeso molecular:277.28JSH-150
CAS:JSH-150 is a highly selective CDK9 inhibitor(IC50 : 1 nM).Fórmula:C24H33ClN6O2SPureza:99.96% - 99.96%Cor e Forma:SolidPeso molecular:505.08THZ1 Hydrochloride
THZ1 Hydrochloride: selective covalent CDK7 inhibitor, IC50 of 3.2 nM; affects CDK12/13 & lowers MYC expression.Fórmula:C31H29Cl2N7O2Cor e Forma:SolidPeso molecular:602.51Dinaciclib
CAS:Dinaciclib (SCH 727965) is a CDK inhibitor that selectively inhibits CDK1, CDK2, CDK5, and CDK9 (IC50 = 3/1/1/4 nM).Fórmula:C21H28N6O2Pureza:98.21% - 99.75%Cor e Forma:SolidPeso molecular:396.49LY3143921
CAS:LY3143921 ((S)-Example 2) is an orally active inhibitor of CDC7 kinase with broad in vitro anticancer activity [1].Fórmula:C16H12FN5OCor e Forma:SolidPeso molecular:309.37BIO
CAS:7BIO triggers nonapoptotic death, blocks FLT3, DYRK1A/2, Aurora B/C kinases.
Fórmula:C16H10BrN3O2Pureza:99.67%Cor e Forma:SolidPeso molecular:356.17PF-562271
CAS:PF-562271 is an effective ATP-competitive, reversible inhibitor of FAK(IC50=1.5 nM) and Pyk2 kinase(IC50=13 nM).Fórmula:C21H20F3N7O3SPureza:97.17% - >99.99%Cor e Forma:SolidPeso molecular:507.49BS-181 dihydrochloride
CAS:BS-181 dihydrochloride: Potent CDK7 inhibitor (IC50: 21 nM), less effective on CDK2/5/9, no impact on CDK1/4/6, halts cancer cell growth, triggers apoptosis.Fórmula:C22H34Cl2N6Cor e Forma:SolidPeso molecular:453.46THZ1
CAS:THZ1 (CDK7 inhibitor) is a selective inhibitor of CDK7, binding to the Cys residue located at the outer end of the classical kinase domain. Cost-effective and quality-assured.Fórmula:C31H28ClN7O2Pureza:97.42% - 99.27%Cor e Forma:SolidPeso molecular:566.05PHA-767491
CAS:PHA-767491 (CAY10572) is a potent ATP-competitive dual Cdc7/CDK9 inhibitor with IC50 of 10 nM and 34 nM, respectively.Fórmula:C12H11N3OPureza:99.49% - >99.99%Cor e Forma:SolidPeso molecular:213.24Ref: TM-T6206
2mg34,00€5mg49,00€1mL*10mM (DMSO)50,00€10mg64,00€25mg92,00€50mg138,00€100mg197,00€200mg295,00€2-Chloropyrazine
CAS:2-Chloropyrazine is used in chemical industry.Fórmula:C4H3ClN2Pureza:98.98% - 99.89%Cor e Forma:Clear Colorless To Yellowish LiquidPeso molecular:114.53RGB-286638 free base
CAS:RGB-286638 free base inhibits CDKs (1-5 nM), weaker on CDK7/6.Fórmula:C29H35N7O4Pureza:98% - 99.91%Cor e Forma:SolidPeso molecular:545.63CKI-7
CAS:CKI-7 is a potent and ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor.Fórmula:C11H14Cl3N3O2SPureza:>99.99%Cor e Forma:SolidPeso molecular:358.67Ref: TM-T19913
1mg73,00€5mg128,00€1mL*10mM (DMSO)140,00€10mg185,00€25mg299,00€50mg405,00€100mg545,00€AT7519 Hydrochloride
CAS:AT7519 Hydrochloride (AT7519 HCl) is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9.Fórmula:C16H18Cl3N5O2Pureza:99.66% - 99.9%Cor e Forma:SolidPeso molecular:418.71SR-4835
CAS:SR-4835 is a highly selective dual inhibitor of CDK12 and CDK13(CDK12: IC50=99 nM, Kd=98 nM; CDK13: Kd=4.9 nM), which disables triple-negative breast cancer (Fórmula:C21H20Cl2N10OPureza:98.09% - >99.99%Cor e Forma:SolidPeso molecular:499.36
